Challenge to Pfizer's Lipitor has some investors worried

Article Abstract:

Indian generic-drug maker Ranbaxy Laboratories Ltd. is challenging the legitimacy of two patents held by Pfizer Inc. for its cholesterol-reducing drug Lipitor. While analysts had initially believed it unlikely that Ranbaxy would win the case, some are now questioning their earlier beliefs in light of evidence that has surfaced during the trial regarding accurate interpretations of the patents and Pfizer's conduct in applying for them.

Product information, India, Securities issued, listed, Regulation, Licensing, and Inspection of Miscellaneous Commercial Sectors, Patent Programs, Securities, Patents, Company securities, Patent/copyright issue, Ranbaxy Laboratories Ltd., United States. District Court (Delaware), Lipitor (Medication)

---

China drug firms to appeal ruling on Pfizer's Viagra

Article Abstract:

A group of 13 pharmaceutical companies in China are appealing a ruling that upheld Pfizer Inc. of the United States patent for Viagara. The Chinese pharmaceutical companies are seeking to produce a generic version of Viagara. Viagara had global sales of approximately $1.6 billion last year.

China, Other Justice, Public Order, and Safety Activities, Patent Law, Interpretation and construction, Economic aspects, Viagara (Medication)

---

Similar abstracts:

• Abstracts: Credit Suisse unit tops rankings in China deals on CCB listing. China-based lender sets IPO price range
• Abstracts: Eutelsat plans IPO to raise expansion cash. Eutelsat continues Falun Gong programming. SES Global suffers a rejection in $1.1 billion bid for New Skies

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.